Related references
Note: Only part of the references are listed.Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
Ayaka Katayama et al.
MODERN PATHOLOGY (2021)
Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer
Sasagu Kurozumi et al.
Oncotarget (2021)
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+breast cancer
J. Veeraraghavan et al.
ANNALS OF ONCOLOGY (2019)
Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
Melissa Krystel-Whittemore et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
Altuna Halilovic et al.
SCIENTIFIC REPORTS (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2018)
Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting
Ziping Wu et al.
ONCOTARGETS AND THERAPY (2018)
Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients
Andrew Dodson et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2018)
Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
David B. Page et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer
Christian F. Singer et al.
CLINICAL CANCER RESEARCH (2017)
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predict Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer
Takahiro Kogawa et al.
ONCOLOGIST (2016)
Updated UK Recommendations for HER2 assessment in breast cancer
Emad A. Rakha et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
Wedad M. Hanna et al.
MODERN PATHOLOGY (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
Ariadna Tibau et al.
NEOPLASIA (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Jens Huober et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
John M. S. Bartlett et al.
LANCET ONCOLOGY (2010)
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
I-Tien Yeh et al.
MODERN PATHOLOGY (2009)
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
Monica M. Reinholz et al.
LANCET ONCOLOGY (2009)
Purposeful selection of variables in logistic regression
Zoran Bursac et al.
SOURCE CODE FOR BIOLOGY AND MEDICINE (2008)
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
Laurent Arnould et al.
CLINICAL CANCER RESEARCH (2007)
Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+in immunohistochemical analysis
R. Merola et al.
EUROPEAN JOURNAL OF CANCER (2006)
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
M Salido et al.
BREAST CANCER RESEARCH (2005)
Share Paper
